atogepant atogepant atogepant, sold under the brand name qulipta, is a medication used to prevent migraines. it is a gepant, an orally active calcitonin gene-related peptide receptor (cgrpr) antagonist. atogepantclinical datatrade namesquliptaother namesagn-241689, mk-8031license data us dailymed: atogepant routes ofadministrationby mouthatc coden02cd07 (who) legal statuslegal status us: ℞-only identifiers iupac name (3s)-n--2-oxospiropyridine-3,6'-5,7-dihydrocyclopentapyridine]-3'-carboxamide cas number1374248-81-3pubchem cid72163100drugbankdb16098chemspider59718640unii7crv8rr151keggd11313chemblchembl3991065chemical and physical dataformulac29h23f6n5o3molar mass603.525 g·mol−13d model (jsmol)interactive image smiles c1(c2c(f)ccc(f)c2f)c(nc(=o)c2cnc3c(c2)c2(c3)c(=o)nc3ncccc32)c(=o)n1cc(f)(f)f inchi inchi=1s/c29h23f6n5o3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20h,8-10,12h2,1h3,(h,38,41)(h,36,39,43)/t13-,16-,20+,28+/m1/s1key:qivuclwgaraqio-olixtkcusa-n it was approved for medical use in the united states in september 2021. medical uses atogepant is indicated for the preventive treatment of episodic migraine in adults. research a study found that atogepant reduced the number of migraine days over twelve weeks.